AUTHORS
Mohamed Mahgoub, MD, PhD, Nidhi Davarapalli2, Heidi Struthers3, Emilee Kotnik, PhD4, Robert Fulton, MS5, Catrina Fronick6, Griffen R Mustion, MS7, Kelly Bolton, MD, PhD8, Haley Abel, PhD9, David H Spencer, MD, PhD10
AFFILIATIONS
1 Washington University in St. Louis, St. Louis, Missouri, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Washington University in St. Louis, St. Louis, Missouri, United States
4 Washington University in St. Louis, St. Louis, Missouri, United States
5 Washington University in St. Louis, St. Louis, Missouri, United States
6 Washington University in St. Louis, St. Louis, Missouri, United States
7 Washington University in St. Louis, St. Louis, Missouri, United States
8 Washington University in St. Louis, St. Louis, Missouri, United States
9 Washington University in St. Louis, St. Louis, Missouri, United States
10 Washington University in St. Louis, St. Louis, Missouri, United States
ABSTRACT
DNA methylation changes in acute myeloid leukemia (AML) can be caused by leukemic transcriptional programs, mutations, or differences in cellular maturation. Alternatively, some changes could represent epimutations: spontaneous epigenetic alterations in normal cells that are stably inherited and could contribute to the expansion of leukemic clones. However, the role of epimutations in AML development is not well understood.
To identify candidates for epimutations in AML, we analyzed whole-genome bisulfite sequencing (WGBS) data from 100 AML patients by performing pairwise comparisons of each sample to data from normal hematopoietic cells. Although most differentially methylated regions (DMRs) were unique, 6,076 were recurrent in >25 samples. These DMR “hotspots” were enriched (>10-fold) for bivalent chromatin, promoters and enhancers. Notably, 26% of recurrent DMRs (1,575) occurred in non-germline imprinted, autosomal regions with intermediate methylation in normal hematopoietic cells (methylation of 0.3-0.7), which is an uncommon and tissue-specific genomic feature linked to conserved regulatory elements. Interestingly, the intermediately methylated regions (IMRs) overlapping DMRs were stable throughout hematopoiesis, and some occurred near hematopoiesis-related genes, including HOXA genes and GATA2. In addition, methylation changes in AML patients at most IMRs were consistently hyper or hypomethylated regardless of subtype or somatic mutations, suggesting these changes arise independently of mutations and their associated transcriptional programs.
To explore the epigenetic structure of IMRs, we analyzed them in hematopoietic stem (HSCs) from 4 normal donors and 10 AML samples using long-read sequencing on the Oxford Nanopore Technologies (ONT) platform. Surprisingly, analysis of haplotype-resolved methylation at IMRs showed both haplotypes had intermediate methylation in normal HSCs, but AML samples were exclusively fully methylated/unmethylated on both haplotypes or they had allele-specific methylation (ASM). ASM at IMRs in AML was associated with allelic chromatin accessibility differences via Fiber-seq, and these regions were nearly entirely conserved in diagnosis and relapse samples from the same patients. We reasoned that ASM at IMRs could be randomly established in single HSCs, such that it manifests as intermediate methylation in bulk normal cells but ASM in clonally expanded AMLs. To test this, we used ONT sequencing to analyze bulk HSCs and 11 single-cell HSC clones from normal CD34+ cells from a single donor. This demonstrated that bulk HSCs had intermediate methylation on each haplotype with no evidence of ASM. In comparison, 70% of IMRs displayed random ASM in the single-cell HSC clones. Further, analysis of RNA-seq data from the HSC clones showed that IMR-linked genes with ASM had allele-specific expression (ASE), including GATA2, demonstrating the direct functional impact of ASM in these regions and that random allele-specific activity is a normal feature of GATA2.
These observations indicate that IMRs represent a previously unreported form of developmentally acquired random “somatic imprinting” in single cells. We hypothesized that DMRs in these regions occur when somatic imprinting is lost, producing pre-existing stable, clonal epimutations. To test this, we analyzed IMRs for hyper or hypomethylated epimutations in AML patients evaluated for persistent clonal mutations in remission by exome sequencing. Indeed, patients with clonal mutations had >3-fold increase in epimutations at IMRs vs. those in who completely cleared their mutations. We next investigated the frequency of epimutations in benign clonal hematopoiesis (CH) by analyzing methylation in blood samples from 5,813 healthy subjects. This showed that the number of epimutations was positively correlated with age and they were increased in people with CH-associated mutations, demonstrating that epimutations at IMRs are pre-existing clonal events.
In summary, we identified genomic regions with developmentally acquired, random allele-specific activity in hematopoietic cells. These somatically imprinted regions are hotspots for pre-leukemic spontaneous epimutations, which occur when imprinting is lost. This phenomenon affects genes with roles in hematopoiesis and AML and could therefore yield new understanding about epigenetic regulation of hematopoiesis and the epigenetic states subject to selection during hematopoietic neoplasms.
DISCLOSURES
David H Spencer, MD, PhD: BrightDx, Inc - Current equity holder in private company; Caris Life Sciences - Patents & Royalties